{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:18:40Z","timestamp":1787231920550,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T00:00:00Z","timestamp":1717286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1053\/j.seminhematol.2024.05.004","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T07:38:54Z","timestamp":1717573134000},"page":"236-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Management of older patients with Hodgkin lymphoma: implications of S1826"],"prefix":"10.1053","volume":"61","author":[{"given":"Marshall","family":"McKenna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyoung","family":"Ryu Tiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-1824","authenticated-orcid":false,"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2024.05.004_sbref0001","series-title":"aERSP. Fast stats: an interactive tool for access to SEER cancer statistics","author":"Surveillance","year":"2022"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.004_bib0002","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ejh.13090","article-title":"Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-A population-based study from Sweden","volume":"101","author":"Bjorkholm","year":"2018","journal-title":"Eur J Haematol"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.05.004_bib0003","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.004_bib0004","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Hodgkin's disease in the elderly: a population-based study","volume":"119","author":"Stark","year":"2002","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.05.004_bib0005","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood-2007-10-115493","article-title":"Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.05.004_bib0006","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1182\/bloodadvances.2022008258","article-title":"The outcome of older adults with classic Hodgkin lymphoma in British Columbia","volume":"6","author":"Cheng","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.004_bib0007","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjh.18564","article-title":"A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race","volume":"200","author":"Shah","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.004_bib0008","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.004_bib0009","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.004_bib0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.004_bib0011","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged >\/=60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"issue":"30","key":"10.1053\/j.seminhematol.2024.05.004_bib0012","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter Phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.004_bib0013","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"S2","key":"10.1053\/j.seminhematol.2024.05.004_bib0014","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/hon.3163_107","article-title":"Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N-AVD) as frontline therapy in older adults with hodgkin lymphoma","volume":"41","author":"Torka","year":"2023","journal-title":"Hematolog Oncol"},{"issue":"17_suppl","key":"10.1053\/j.seminhematol.2024.05.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.05.004_bib0016","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood-2023-180114","article-title":"Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged \u226560 years) with advanced stage hodgkin lymphoma enrolled on SWOG S1826","volume":"142","author":"Rutherford","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.004_bib0017","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/hematology.2022000346","article-title":"Fitness and frailty in myeloma","volume":"2022","author":"Pawlyn","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.05.004_bib0018","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified Geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.05.004_bib0019","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.2023022611","article-title":"Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action","volume":"143","author":"Bhatt","year":"2024","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.05.004_bib0020","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.05.004_bib0021","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/bloodadvances.2021004645","article-title":"Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma","volume":"5","author":"Orellana-Noia","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.004_bib0022","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/oxfordjournals.annonc.a057939","article-title":"Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study","volume":"2","author":"Enblad","year":"1991","journal-title":"Ann Oncol"},{"issue":"7-8","key":"10.1053\/j.seminhematol.2024.05.004_bib0023","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/028418602321028283","article-title":"Swedish Lymphoma Study G. Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy","volume":"41","author":"Enblad","year":"2002","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.004_bib0024","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jha2.202","article-title":"Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years","volume":"2","author":"Wahlin","year":"2021","journal-title":"EJHaem"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.05.004_bib0025","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.004_bib0026","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.004_bib0027","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/hon.2830","article-title":"Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland","volume":"39","author":"Moccia","year":"2021","journal-title":"Hematol Oncol"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.05.004_bib0028","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","article-title":"How I treat elderly patients with diffuse large B-cell lymphoma","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.004_bib0029","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1182\/hematology.2020000099","article-title":"Approaches to aggressive B-cell lymphomas in less fit patients","volume":"2020","author":"Bartlett","year":"2020","journal-title":"Hematology"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.05.004_bib0030","first-page":"2566","article-title":"How I treat older patients with DLBCL in the frontline setting","volume":"141","author":"Lugtenburg","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.004_bib0031","first-page":"1087","article-title":"Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen","volume":"20","author":"Weekes","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.004_bib0032","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2023.01.014","article-title":"Characteristics and outcomes of older patients with classical Hodgkin lymphoma: an Australasian lymphoma alliance, and lymphoma and Related Diseases Registry Study","volume":"23","author":"Goh","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.004_bib0033","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.16525","article-title":"First-line treatment in older patients with Hodgkin lymphoma: a surveillance, epidemiology, and end results (SEER)-medicare population-based study","volume":"190","author":"Rodday","year":"2020","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.05.004_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28373","article-title":"Association of treatment intensity with survival in older patients with Hodgkin lymphoma","volume":"4","author":"Rodday","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.05.004_bib0035","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.004_bib0036","first-page":"438","article-title":"Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.004_bib0037","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.17073","volume":"193","author":"Gibb","year":"2021","journal-title":"British J Haematol"},{"key":"10.1053\/j.seminhematol.2024.05.004_bib0038","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood-2021-147863","article-title":"Nivolumab first-line therapy for elderly, frail Hodgkin lymphoma patients: Niviniho, a Lysa phase II study","volume":"138","author":"Lazarovici","year":"2021","journal-title":"Blood"},{"issue":"S2","key":"10.1053\/j.seminhematol.2024.05.004_bib0039","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hon.3163_106","article-title":"Pembrolizumab as first therapy for Hodgkin lymphoma is deliverable in older or ABVD-ineligible patients, allows subsequent therapy, and gives adequate survival","volume":"41","author":"Dickinson","year":"2023","journal-title":"Hematolog Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.05.004_bib0040","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.004_bib0041","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-136583","article-title":"Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients","volume":"136","author":"Yasenchak","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.05.004_bib0042","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.004_bib0043","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1182\/blood-2023-190260","article-title":"Brentuximab Vedotin in frontline therapy of Hodgkin Lymphoma in patients with significant comorbidities ineligible for standard chemotherapy (SGN35-015 Part E)","volume":"142","author":"Yasenchak","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.05.004_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"The Lancet Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.004_bib0045","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bjh.18947","article-title":"\u2018ACOPP\u2019 chemotherapy for older and less fit patients with Hodgkin lymphoma\u2014A multicentre, retrospective study","volume":"202","author":"Wilson","year":"2023","journal-title":"British J Haematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.05.004_bib0046","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2018-99-119363","article-title":"B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)","volume":"132","author":"Boell","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.05.004_bib0047","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood.2023021564","article-title":"The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients","volume":"143","author":"Ghesqui\u00e8res","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.05.004_bib0048","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1080\/10428194.2019.1608529","article-title":"Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (>\/=70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)","volume":"60","author":"Salvi","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2024.05.004_bib0049","unstructured":"Phase II Trial of individualized immunotherapy in early-stage unfavorable classical Hodgkin lymphoma (INDIE). NCT04837859."},{"key":"10.1053\/j.seminhematol.2024.05.004_bib0050","unstructured":"HD21 for advanced stages. NCT02661503."},{"key":"10.1053\/j.seminhematol.2024.05.004_bib0051","unstructured":"Fitness-adapted, pembrolizumab-based therapy for untreated classical Hodgkin lymphoma patients 60 years of age and above. NCT05404945."},{"key":"10.1053\/j.seminhematol.2024.05.004_bib0052","unstructured":"A study of brentuximab vedotin with Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL). NCT01716806."},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.004_bib0053","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bjh.15741","article-title":"Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial","volume":"185","author":"B\u00f6ll","year":"2019","journal-title":"British J Haematol"},{"key":"10.1053\/j.seminhematol.2024.05.004_bib0054","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.HS9.0000890896.83681.49","article-title":"T082: AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients","volume":"6","author":"\u00d6vergaard","year":"2022","journal-title":"HemaSphere"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T13:04:43Z","timestamp":1726837483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0037196324000684"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.05.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Management of older patients with Hodgkin lymphoma: implications of S1826","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}